Monogram Biosciences, Inc.

Laboratory Corporation of America Holdings

Colombe Chappey

Neil T Parkin

Christos J Petropoulos

John William Winslow

Michael R Bates

Jeff Sperinde

Mary T Wrin

Weidong Huang

Ellen Paxinos

Andrea Gamarnik

In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.

Her2 diagnostic methods

The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.

Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors

Method for determining human immunodeficiciency virus type 1 (HIV-1) hypersusceptibility to the protease inhibitor amprenavir

Growing community of inventors

San Francisco, CA, United States of America

Colombe Chappey